Drug Profile
Research programme: Alzheimer's disease therapeutics - Archer Pharmaceuticals
Alternative Names: ARC 050; ARC 069Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Archer Pharmaceuticals
- Class Antidementias
- Mechanism of Action Amyloid precursor protein secretase inhibitors; Calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA
- 21 Oct 2008 Preclinical trials in Alzheimer's disease in USA (unspecified route)